Design Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2017-01-01
- Employees
- 124
- Market Cap
- $278.5M
- Website
- http://www.designtx.com
- Introduction
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
- First Posted Date
- 2025-03-13
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Design Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06874010
- Locations
- 🇦🇺
Scientia Clinical Research Ltd, Sydney, New South Wales, Australia
🇦🇺Doherty Clinical Trials, East Melbourne, Victoria, Australia
🇦🇺Nucleus Network, Melbourne, Victoria, Australia
A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Design Therapeutics, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06772870
- Locations
- 🇦🇺
Nucleus Network, Level 5, 89 Commercial Road, Melbourne, Victoria, Australia
Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Design Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT05573698
- Locations
- 🇺🇸
Clinilabs, Eatontown, New Jersey, United States
Study to Evaluate DT-216 in Adult Patients With Friedreich Ataxia
- First Posted Date
- 2022-03-17
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- Design Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT05285540
- Locations
- 🇺🇸
Clinilabs, Eatontown, New Jersey, United States